Dilated cardiomyopathy - guidelines for personalization of care

Antonella Spinelli1, Gaetano Marino1, Alfredo Macchiusi1

  • 1Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital - ASL Roma 1, Rome.

Insights

This case study highlights a young man with dilated cardiomyopathy (DCM) and sudden cardiac death (SCD) risk. A subcutaneous defibrillator was chosen due to psychiatric conditions, offering personalized protection against SCD.

Area of Science:

  • Cardiology
  • Genetics
  • Psychiatry

Background:

  • Dilated cardiomyopathy (DCM) involves genetic and environmental factors.
  • Cardiac magnetic resonance imaging aids etiological diagnosis and treatment.
  • Sudden cardiac death (SCD) is a risk in DCM, especially with family history.

Purpose of the Study:

  • To present a challenging case of DCM in a young male with complex comorbidities.
  • To discuss the etiological investigation and therapeutic decision-making process.
  • To evaluate defibrillator options for SCD risk management in this patient.

Main Methods:

  • Case report of a young male patient with DCM, severe left ventricular dysfunction, and a family history of SCD.
  • Consideration of etiological factors including psychiatric pathology and substance addiction.
  • Evaluation of wearable defibrillator versus subcutaneous implantable cardioverter-defibrillator (SCD-ICD) for SCD prevention.

Main Results:

  • The patient presented with DCM, significant ventricular dysfunction, and SCD risk.
  • Psychiatric conditions and potential non-adherence precluded the use of a wearable defibrillator.
  • A subcutaneous defibrillator was implanted, representing a personalized therapeutic strategy.

Conclusions:

  • Personalized therapeutic choices are crucial in complex DCM cases.
  • Subcutaneous defibrillators offer an alternative for SCD prevention when adherence to other devices is a concern.
  • Multidisciplinary management is essential for patients with DCM and co-existing conditions.

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
627
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331